step 1 trial semaglutide 2.4 mg weight loss nejm 2021 SURPASS-2 (NEJM 2021) was the definitive head-to-head: tirzepatide vs 1.0 (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions Wegovy FDA Approval: CV Risk
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17



























